MedPath

Inhibitory effect of local administration of Lactobacillus rhamnosus K03 (L8020) on peri-implantitis with suppuratio

Phase 1
Recruiting
Conditions
Peri-implantitis Active
D057873
Registration Number
JPRN-jRCTs061230059
Lead Sponsor
Yasuda Keisuke
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

1. Persons who are 18 years of age or older at the time consent is obtain
2. Those who can obtain written consent from the individual to participate in this study
3. Patients with implants that meet the diagnostic criteria for peri-implantitis for at least one year at the time of study entry.
Peri-implantitis is defined as patients who meet the following diagnostic criteria
i) Inflammation around the implant
ii) Bone resorption around the implant
4. Patients with implants that have been known to drain for at least 3 months and have drained within 1 week prior to enrollment.

Exclusion Criteria

1. Patients who have received a lactic acid bacteria preparation, bifidobacteria preparation, butyric acid bacteria preparation, or this drug as a prescription drug within 3 months prior to the start of administration of this drug.
2. Patients who have experienced serious adverse reactions to lactic acid bacteria, bifidobacteria, butyric acid bacteria, or this drug as ethical drugs in the past.
3. Patients who have received antimicrobial agents administered topically in the oral cavity or systemically by oral administration, etc. within 7 days.
4. Patients already using this drug.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement rate to peri-implantitis Remission after 7 days of L8020 treatment in patients with peri-implantitis Active
Secondary Outcome Measures
NameTimeMethod
Changes in the structure of the bacterial flora comprising the peri-implant sulcus
© Copyright 2025. All Rights Reserved by MedPath